117.43
0.63%
+0.74
Illumina Inc stock is currently priced at $117.43, with a 24-hour trading volume of 1.38M.
It has seen a +0.63% increased in the last 24 hours and a -11.81% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $117.2 pivot point. If it approaches the $118.7 resistance level, significant changes may occur.
Illumina Inc Stock (ILMN) Financials Data
Illumina Inc (ILMN) Revenue 2024
ILMN reported a revenue (TTM) of $4.50 billion for the quarter ending December 31, 2023, a -1.72% decline year-over-year.
Illumina Inc (ILMN) Net Income 2024
ILMN net income (TTM) was -$1.16 billion for the quarter ending December 31, 2023, a +73.66% increase year-over-year.
Illumina Inc (ILMN) Cash Flow 2024
ILMN recorded a free cash flow (TTM) of $282.00 million for the quarter ending December 31, 2023, a +481.08% increase year-over-year.
Illumina Inc (ILMN) Earnings per Share 2024
ILMN earnings per share (TTM) was -$7.34 for the quarter ending December 31, 2023, a +73.79% growth year-over-year.
Illumina Inc Stock (ILMN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Thaysen Jacob | Chief Executive Officer |
Feb 22 '24 |
Buy |
135.29 |
7,330 |
991,672 |
14,861 |
Hoyt Aimee L | SVP, Chief People Officer |
Nov 07 '23 |
Sale |
112.84 |
315 |
35,545 |
8,314 |
TOUSI SUSAN H | SVP, Chief Commercial Officer |
Aug 22 '23 |
Sale |
167.04 |
500 |
83,520 |
45,524 |
TOUSI SUSAN H | SVP, Chief Commercial Officer |
Jul 24 '23 |
Sale |
190.08 |
500 |
95,040 |
46,022 |
TOUSI SUSAN H | SVP, Chief Commercial Officer |
Jun 22 '23 |
Sale |
200.00 |
500 |
100,000 |
46,522 |
EPSTEIN ROBERT S | Director |
May 25 '23 |
Option Exercise |
71.09 |
7,600 |
540,284 |
14,764 |
Illumina Inc Stock (ILMN) Latest News
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Zacks Investment Research
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Zacks Investment Research
Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'
Benzinga
Wall Street Breakfast: The Week Ahead
Seeking Alpha
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks Investment Research
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
About Illumina Inc
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):